Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Conditions
- Non-alcoholic Steatohepatitis (NASH)
Interventions
- DRUG: Tropifexor (LJN452)
- DRUG: Cenicriviroc (CVC)
Sponsor
Novartis Pharmaceuticals
Collaborators